Biotech pioneering 'targeted protein degrader' drugs that eliminate disease-causing proteins, focused on immunology and inflammation.
Biotech pioneering 'targeted protein degrader' drugs that eliminate disease-causing proteins, focused on immunology and inflammation.
Has no approved medicine, so income comes from partners: upfront and milestone payments from Sanofi and Gilead under research collaborations and licences. Spending goes on clinical trials of its own oral drugs, led by KT-621 for immune diseases. The business is funded by partner payments and cash raised from investors.
Moat: narrow (IP / patents, process know-how). Early leadership in oral targeted-protein-degrader chemistry, patent-protected, with validated pharma partnerships.
Headquarters: Watertown, Massachusetts, US · Founded: 2016 · Employees: 238
Size Kymera Therapeutics (KYMR) is a United States Health Care company (Biotechnology) with a market value of $10.3B, the 749th largest of 3,085 United States companies the cockpit tracks. Shares closed at $121.13 on 18 Nov 2026.
Performance Over six months the shares gained 50.2%, against +23.0% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 133.8% over the last twelve months (peer median +25.6%); the operating margin is -396.0% (peer median 10.9%).
Valuation It trades at 92.4× enterprise value to sales against a peer median of 9.5× (2nd most expensive of 17).
Capital Return on invested capital runs 59.6 points below its cost of capital (15.2% WACC).
Backlog Backlog (remaining performance obligations) was $51.4M at 31 Dec 2024 — 1.1 years of trailing revenue. Backlog detail →
Short interest Short interest is 9.8% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $102M | $39.2M | $47.1M | $78.6M | $46.8M |
| Revenue growth | — | -17% | -40% | +68% | — |
| Gross profit | $94.1M | $30.9M | $39.7M | $75.0M | $43.8M |
| EBITDA | -$397M | -$337M | -$249M | -$162M | -$158M |
| Net income | -$349M | -$311M | -$224M | -$147M | -$155M |
| Free cash flow | -$289M | -$234M | -$207M | -$137M | -$156M |
| Capital expenditure | $1.33M | $1.45M | $12.8M | $34.5M | $2.84M |
| Total debt | $76.6M | $82.3M | $87.8M | $84.7M | $17.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Kymera Therapeutics KYMR | $10.3B | +50% | +134% | -396% | 92.4× | n/a |
| Arvinas ARVN | $443M | -26% | -12% | -10% | n/a | n/a |
| C4 Therapeutics CCCC | $325M | -25% | +7% | -316% | 5.4× | n/a |
| Nurix Therapeutics NRIX | $1.54B | -14% | +739% | 41% | 0.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KYMR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.8% | -5.4% | 7th highest of 21 |
| 6-month return | +50.2% | +23.0% | 6th highest of 21 |
| Distance from 52-week high | -15.2% | -26.2% | 7th highest of 21 |
| Revenue growth (TTM) | +133.8% | +25.6% | 3rd highest of 17 |
| Operating margin | -396.0% | 10.9% | 2nd lowest of 17 |
| EV / Sales | 92.4× | 9.5× | 2nd most expensive of 17 |
| ROIC minus cost of capital | -59.6 pp | -1.0 pp | 2nd lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics KYMR | United States | $10.3B | +50% | +134% | -396% | 92.4× | n/a | n/a |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 3.7× | 6.2% | +2.3% |
| Halozyme Therapeutics HALO | United States | $10.9B | +39% | +45% | 57% | 7.3× | -0.3% | +39.2% |
| Bio-Techne TECH | United States | $11.4B | +56% | +1% | 21% | 9.2× | 31.6% | +5.5% |
| Krystal Biotech KRYS | United States | $9.34B | +4% | +26% | 48% | 18.0× | 13.1% | +26.0% |
| Vaxcyte PCVX | United States | $9.26B | +24% | n/a | n/a | n/a | n/a | n/a |
| BioMarin Pharmaceutical BMRN | United States | $11.9B | +22% | +20% | 19% | 4.2× | 8.2% | +12.0% |
| Cspc Pharma 1093.HK | Hong Kong | $12.0B | +10% | +25% | 28% | 2.1× | -10.7% | +0.1% |
| ALTEOGEN 196170.KS | South Korea | $8.80B | -56% | +61% | 53% | 35.1× | 24.6% | +38.5% |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | 12% | 9.8× | 36.9% | +19.8% |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |
| Elanco Animal Health ELAN | United States | $13.3B | +28% | +12% | 8% | 3.2× | 32.9% | +7.6% |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | 16.2× | n/a | n/a |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | 11.3× | 47.2% | +16.6% |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | 1,000.7× | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 8.0× | n/a | n/a |
| BridgeBio Pharma BBIO | United States | $15.2B | +14% | +167% | -37% | 19.1× | n/a | n/a |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| Neurocrine Biosciences NBIX | United States | $16.5B | +5% | +38% | 25% | 4.4× | -1.5% | +22.3% |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | 14.0× | n/a | n/a |
Kymera Therapeutics reported $51.4M of remaining performance obligations at 31 Dec 2024 and up 3% from the previous quarter. That is 1.1 years of trailing revenue already under contract. Book-to-bill last quarter: 1.23.